Palatin Technologies (PTN) Asset Writedowns and Impairment (2019 - 2022)
Palatin Technologies' (PTN) quarterly Asset Writedowns and Impairment came in at -$34413.0 in Q2 2022, down 138.13% YoY from $90259.0 in Q2 2021, and down 138.54% on a QoQ basis from $89284.0 in Q1 2022.
Palatin Technologies (PTN) Asset Writedowns and Impairment (2019 - 2022) Analysis & Trends
Palatin Technologies (PTN) has 4 years of Asset Writedowns and Impairment data on file, last reported at -$34413.0 in Q2 2022.
- Quarterly Asset Writedowns and Impairment fell 138.13% year-over-year to -$34413.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $234443.0 (down 29.14% YoY) and the FY2022 annual result came in at $234443.0, down 29.14% from the prior year.
- Asset Writedowns and Impairment eased to -$34413.0 in Q2 2022, from $89284.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $91481.0 in Q3 2021 to a low of -$34413.0 in Q2 2022.
- A 4-year average of $71986.7 and a median of $77602.5 in 2020 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment increased 20.81% — and 2022, when it sank 138.13%.
- Tracing PTN's Asset Writedowns and Impairment over 4 years: stood at $72790.0 in 2019, then gained by 5.41% to $76725.0 in 2020, then gained by 14.81% to $88091.0 in 2021, then plunged by 139.07% to -$34413.0 in 2022.
- The last three Asset Writedowns and Impairment figures came in at -$34413.0 (Q2 2022), $89284.0 (Q1 2022), and $88091.0 (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -34,413.00 |
| Jun 30, 2022 | -34,413.00 |
| Mar 31, 2022 | 89,284.00 |
| Mar 31, 2022 | 89,284.00 |
| Dec 31, 2021 | 88,091.00 |
| Dec 31, 2021 | 88,091.00 |
| Sep 30, 2021 | 91,481.00 |
| Sep 30, 2021 | 91,481.00 |
| Jun 30, 2021 | 90,259.00 |
| Jun 30, 2021 | 90,259.00 |
| Mar 31, 2021 | 88,133.00 |
| Mar 31, 2021 | 88,133.00 |
| Dec 31, 2020 | 76,725.00 |
| Dec 31, 2020 | 76,725.00 |
| Sep 30, 2020 | 75,722.00 |
| Sep 30, 2020 | 75,722.00 |
| Jun 30, 2020 | 78,480.00 |
| Jun 30, 2020 | 78,480.00 |
| Mar 31, 2020 | 75,175.00 |
| Mar 31, 2020 | 75,175.00 |